Trial Profile
Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary)
- Indications Alopecia
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 22 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Apr 2013 New trial record